Table 3 Combined genotype and allele frequencies of the MTHFR 3′-UTR polymorphisms for ischemic stroke patients and control subjects.

From: Interplay between 3′-UTR polymorphisms in the methylenetetrahydrofolate reductase (MTHFR) gene and the risk of ischemic stroke

Genotypes

Controls freq. (n = 411)

Case freq. (n = 511)

AOR (95% CI)

P

P

MTHFR 2572/4869/5488/6685 genotype combination

CC/CC/CC/TT

0.652

0.644

1.000 (reference)

  

CC/CC/CC/TC

0.029

0.002

0.095 (0.012–0.761)

0.027

0.149

CC/CC/CT/TT

0.000

0.002

0.393 (0.021–7.323)

0.531

0.680

CA/CC/CC/TT

0.022

0.065

2.922 (1.342–6.361)

0.007

0.077

CA/CC/CC/TC

0.141

0.145

1.106 (0.745–1.642)

0.618

0.680

CA/CC/CT/TT

0.024

0.010

0.475 (0.157–1.438)

0.188

0.528

CA/CC/CT/TC

0.010

0.002

0.309 (0.034–2.844)

0.299

0.581

CA/CG/CT/TT

0.085

0.092

1.218 (0.746–1.989)

0.431

0.677

AA/CC/CC/TT

0.005

0.002

0.524 (0.044–6.192)

0.608

0.680

AA/CC/CC/CC

0.005

0.014

3.004 (0.575–15.704)

0.192

0.528

AA/CC/CT/TC

0.005

0.002

0.628 (0.056–7.100)

0.707

0.707

AA/CG/CT/TC

0.007

0.002

0.295 (0.027–3.213)

0.317

0.581

MTHFR 2572/4869/5488/6685 allele combination

C-C-C-T

0.812

0.807

1.000 (reference)

  

C-C-C-C

0.016

0.001

0.062 (0.008–0.477)

0.001

0.006

C-C-T-T

0.001

0.001

0.809 (0.050–12.96)

1.000

1.000

C-G-C-T

0.000

0.002

4.043 (0.194–84.42)

0.505

0.758

C-G-T-T

0.001

0.000

0.270 (0.011–6.632)

0.447

0.758

C-G-T-C

0.001

0.000

0.270 (0.011–6.632)

0.447

0.758

A-C-C-T

0.016

0.035

2.239 (1.178–4.257)

0.013

0.078

A-C-C-C

0.081

0.088

1.086 (0.779–1.514)

0.673

0.897

A-C-T-T

0.016

0.014

0.871 (0.406–1.865)

0.846

1.000

A-C-T-C

0.005

0.001

0.202 (0.023–1.814)

0.180

0.600

A-G-C-T

0.000

0.003

5.660 (0.292–109.9)

0.258

0.619

A-G-T-T

0.047

0.048

1.016 (0.659–1.566)

1.000

1.000

A-G-T-C

0.003

0.000

0.162 (0.008–3.377)

0.200

0.600

  1. The P-value was calculated by multiple logistic regression on the basis of risk factors such as age, gender, hypertension, hyperlipidemia, and diabetes mellitus. Abbreviations are defined in Table 1.
  2. The false discovery rate-adjusted P value for multiple hypothesis testing using the Benjamini-Hochberg method.